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Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease caused by
progressive loss of upper and lower motor neurons. Mutations in superoxide dismutase 1
(SOD1) are a leading cause of ALS, responsible for up to 20% of familial cases. Although
the exact mechanism by which mutant SOD1 causes disease remains unknown, multiple
studies have shown that reduction of the mutant species leads to delayed disease onset
and extension of lifespan of animal models. This makes SOD1 an ideal target for gene
therapy coupling adeno associated virus vector (AAV) gene delivery with RNAi molecules.
In this reviewwe summarize the studies done thus far attempting to decrease SOD1 gene
expression, using AAV vectors as delivery tools, and RNAi as therapeutic molecules.
Current hurdles to be overcome, such as the need for widespread gene delivery through
the entire central nervous system (CNS), are discussed. Continued efforts to improve
current AAV delivery methods and capsids will accelerate the application of these
therapeutics to the clinic.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular disorder, resulting in loss of
upper and lower motor neurons, leading to paralysis, and death within 3–5 years after diagnosis
(Orsini et al., 2015). Mutations in super oxide dismutase 1 (SOD1) are responsible for over 20% of
familial, or inherited, ALS cases (Renton et al., 2014). Since its discovery as the first ALS causative
gene over 20 years ago, SOD1 has been extensively studied (Rosen et al., 1993). Although the
exact mechanism of disease has not been elucidated, in vitro and in vivo studies have shown that
mutations in SOD1 lead to misfolding and aggregation of the mutant protein species (Rakhit and
Chakrabartty, 2006; Peters et al., 2015b). Additionally, as SOD1 knockout mice do not develop a
paralysis phenotype (Reaume et al., 1996), nor do all SOD1 mutations cause a complete loss of
dismutase function, and enzymatically inactive mutant SOD1 still causes motor neuron disease
(Borchelt et al., 1994; Wang et al., 2002), it is widely accepted that mutant SOD1 acts through a
toxic gain of function mechanism.
A common therapeutic approach for gain of function diseases is reduction of the toxic gene
product. Loss of Sod1 in mice does not lead to paralysis or motor neuron loss. Additionally, there is
no survival benefit in expressing mutant human SOD1 in the presence of mouse Sod1 compared to
Sod1 null background (Bruijn et al., 1998). This would imply that SOD1 reduction is likely to be a
safe therapeutic approach. However, there does appears to be increased motor neuron vulnerability
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in response to stress and injury in both Sod1−/− and Sod1+/−
mice (Reaume et al., 1996; Saccon et al., 2013). While this
suggests a potential effect due to SOD1 loss of function, complete
knockout mouse models are not accurate representation of gene
reduction strategies, such as RNAi. In the Sod1−/− mouse,
the enzyme is absent from embryonic development, while an
RNAi approach would reduce, but not completely eliminate (see
below), the levels of an already existing protein. Nevertheless,
since the Sod1+/− mouse does have a mild phenotype, ideal
therapies would be allelic specific, reducing only the mutant
gene product. Meanwhile, future clinical trials could consider
supplementation with SOD1 enzyme replacement therapy.
Gene therapy for familial ALS has made substantial headway
in recent years, especially as the number of preclinical studies
and clinical trials using RNAi therapies and AAV vectors have
increased rapidly (Borel et al., 2014). Multiple studies have
approached SOD1-ALS treatment through the use of AAV
delivered RNAi in both mouse and rat models of ALS, as well
as target engagement and safety studies in normal monkeys.
Although the studies have had various degrees of success, they
have consistently shown AAV-RNAi to be a viable therapeutic
approach.
REDUCTION OF SOD1 IS NECESSARY IN
BOTH NEURONS AND ASTROCYTES
Some of the initial work aimed at assessing the therapeutic
potential of reducing mutant SOD1 expression used transgenic
mouse models. The most widely used mouse model is the
SOD1G93A mouse, which contains multiple copies of the
mutated human SOD1 gene. This mouse reproduces the patient
phenotype, including the progressive loss of motor neurons
and development of hind limb paralysis. The first study (Saito
et al., 2005) crossed mice constitutively expressing an anti-
SOD1 siRNA transgene with SOD1G93A mice, and the double
transgenic mice showed no signs of disease. In the study, SOD1
expression was reduced in all cells, presumably from the first
stages of embryonic development. Additionally, the shRNA used
was not specific for human SOD1 but also reduced mouse
Sod1 expression. The absence of a phenotype associated with
loss of SOD1 activity in these mice supports the notion that
non-allele specific silencing of SOD1 is likely to be safe in
humans. A parallel study (Boillee et al., 2006) used conditional
knock-out mice where the mutant SOD1 transgene was flanked
by loxP sites. These mice were crossed with other transgenic
mice expressing Cre under neuronal or microglial/macrophage
promoters, leading to cell type-specific excision of SOD1. Both
mouse lines displayed an increase in survival, but elimination of
SOD1 in neurons delayed onset, while in glia it slowed disease
progression. These two studies in transgenic animals highlighted
early on that althoughmotor neurons are selectively vulnerable in
ALS, targeting non-neuronal cells is likely crucial to fully treat the
disease.
The first gene therapy studies for SOD1-ALS focused on viral
vector delivered RNAi molecules to spinal cord motor neurons.
The largest increase in lifespan in a SOD mouse model was
documented for an approach based on intramuscular injections
of a lentivirus encoding a shRNA against SOD1. The vector was
delivered at postnatal day 7 by direct injection into multiple
muscle groups, resulting in a survival increase of 77%, due to a
delay in disease onset; suggesting it was successful in silencing
SOD1 expression in motor neurons. The muscles injected
included the hindlimb, to target lower motor neurons; as well
as the facial, tongue, and intercostal muscles, since ALS has not
only mobility, but feeding and respiratory deficits as well. While
these results were promising, the large number of injections
required made clinical translation challenging. It is interesting
to note that the researchers chose injections into muscle to take
advantage of the retrograde transport capabilities of the (equine
infectious anemia virus) EIAV lentivirus vector pseudotyped
with the Rabies G envelope glycoprotein, and specifically target
the innervating neurons. Thus, it is not surprising that while
disease onset was delayed, the length of disease duration was not
increased further supporting the notion that motor neurons are
mediators of disease onset, but progression is also dependent on
expression of mutant SOD1 in glia (Ralph et al., 2005). Another
study used a lentivirus to deliver an shRNA through bilateral
injection into the lumbar spinal cord, in 40-day-old SOD1G93A
mice. This injection approach was successful in targeting motor
neurons in the lumbar spinal cord. However, there was no
increase in lifespan, despite a 60% improvement in motor neuron
survival (Raoul et al., 2005). These outcomes further emphasize
the importance of targeting multiple cell types throughout the
spinal cord.
Widespread transduction is likely necessary to completely
prevent cell autonomous and non-autonomous toxic
mechanisms from triggering a cascade of events that ultimately
lead to complete loss of motor function. Reduction of mutant
SOD1 in motor neurons and glia, and possibly also muscle,
has been shown to be critical to prevent disease manifestation.
The presence of SOD1 in non-neuronal cells is important
for disease progression and multiple studies have shown that
motor neurons are selectively vulnerable to astrocyte-mediated
toxicity (Julien, 2007). Studies in different SOD1 mouse models
have shown that reduction of SOD1 specifically in astrocytes
leads to an increase in survival (Boillee et al., 2006; Yamanaka
et al., 2008). Additionally, astrocytes from SOD1 mice are
toxic to motor neurons, both in vivo and in vitro (Nagai et al.,
2007; Di Giorgio et al., 2008; Haidet-Phillips et al., 2011). An
increase in astrocytosis is also associated with SOD1 astrocyte
driven disease progression. A recent study aimed to definitively
answer the question as to whether neurons or astrocytes alone
can be therapeutic targets using a gene transfer approach.
AAV vectors encoding SOD1-specific artificial microRNAs
(amiRNAs) under cell specific promoters were infused into
the lateral ventricles of neonate SOD1 mice (Dirren et al.,
2015). An AAV6 vector carrying the cytomegalovirus (CMV)
promoter (shown to have strong propensity to transduce motor
neurons with this type of serotype and delivery method Dirren
et al., 2014) extended survival by 26% while an AAV9 vector
carrying a GFAP glial promoter increased survival by 14%.
Unfortunately, the combined injection of both AAV vectors
showed no additional benefit, and fell short of the large increase
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in lifespan documented with the intravenous delivery of AAVs
encoding shRNA or amiRNA under ubiquitous promoters.
However, this could be due to the need to half the dose of both
vectors for combined infusion, in order to maintain the same
injection volume. Studies are also underway testing a single
bicistronic AAV vector where the therapeutic artificial miRNA
is expressed from both the neuronal synapsin 1 and glial GFAP
promoters. The bicistronic AAV vector appears to have superior
therapeutic effect based on motor performance compared to
AAV vectors targeting a single cell type (Bobela-Aebischer et al.,
2016).
THERAPEUTIC SUCCESS OF SYSTEMIC
AAV-RNAI DELIVERY IS AGE DEPENDENT
The discovery that AAV9 is capable of crossing the blood brain
barrier after systemic administration opened a new avenue for
development of a gene therapy approach capable of tackling ALS
in a global manner (Foust et al., 2009). The first AAV9 based
study used an H1 promoter driven shRNA (Foust et al., 2013)
and reported a 39% increase in median survival when delivered
to SOD1 mice at postnatal day 1 (P1), and 30% when delivered
at postnatal day 21 (P21). The spinal cord transduction profile
of AAV9 injected systemically changes from motor neurons in
neonates to mostly glia in older animals (Foust et al., 2009).
Consistently P1 injections led to transduction of more motor
neurons (64%) than glia (34%), while it was the reverse for P21
injection with transduction of fewer motor neurons (8%) than
glia (54%). The degree of SOD1 protein reduction in the spinal
cord was also age dependent with 60% for P1, but only by 45%
after P21 injection. In this study, mice were also injected at 85
days of age, when disease symptoms are starting to manifest,
leading to a 23% increase in survival. These results raise the
question of how late in disease progression is an AAV-RNAi
intervention likely to have a therapeutic effect. This has been
further confirmed by a recent study (Borel et al., 2016), which
also used an intravenous infusion, of AAVrh10, to deliver an
artificial microRNA specific to SOD1. Mice were treated at 56–
68 days, when early signs of disease are already apparent at the
molecular and biochemical levels. Testing therapeutic efficacy
in early symptomatic adult mice is more relevant compared to
neonatal or P21 interventions since ALS patients are diagnosed as
adults and often at early stages of disease progression. Treatment
with AAVrh10-amiRNA reduced SOD1 mRNA in transduced
cells and increased lifespan by 21%, an outcome similar to the
previous treatment initiated at 85 days of age. Since AAV9 (and
AAVrh10) target mostly glia after an postnatal day 1 intravenous
infusion (Zhang et al., 2011; Yang et al., 2014), it is clear that
SOD1 reduction in glial alone is not sufficient, as shown in
previous studies with conditional knock-out SOD1 mice (Boillee
et al., 2006), and it is likely that more motor neurons need to be
transduced to achieve greater therapeutic efficacy. Thus, while
an intravenous infusion is the easiest delivery method, current
AAV vectors are not efficient enough at crossing the blood
brain barrier in adult mice to transduce the majority of cells in
the CNS.
UPPER MOTOR NEURONS, AS WELL AS
MUSCLE, PLAY A ROLE IN DISEASE
PROGRESSION
It has been hypothesized that ALS is caused by a “dying
back” mechanism, where degeneration starts in muscle, travels
up the axons to the spinal cord motor neurons and then
to the cortical layer V motor neurons in the brain. AAV6
has been shown to efficiently transduce skeletal muscle as
well as undergo retrograde transport to motor neurons after
intramuscular injection (Kaspar et al., 2003; Gregorevic et al.,
2004). Thus, several studies used AAV6 to deliver an SOD1-
specific shRNA in SOD1 mice, to reduce the mutant protein
in muscle as well as in the central nervous system (CNS).
In the first study, adult SOD1 mice received an intravenous
infusion of AAV6-shRNA vector resulting in 50% reduction
in SOD1 protein in skeletal muscle. However, <5% of motor
neurons were transduced, and there was no apparent reduction
in SOD1 levels in the spinal cord (Towne et al., 2008). In
a subsequent study (Towne et al., 2011), AAV6-shRNA was
injected directly into multiple muscle groups in neonate SOD1
mice, similar to the EIAV lentivirus study, but there was no
change in survival. This was surprising as there was efficient
retrograde transport of AAV6 to motor neurons as evidenced
by the >50% reduction of SOD1 mRNA level in transduced
cells. This discrepancy is potentially due to the lower number
of motor neurons transduced in the AAV6 study compared
to the EIAV lentivirus study (40% vs. >50% in the lumbar
spinal cord, respectively), or differences in shRNA efficacy. In
a separate experiment, an shRNA against SOD1 was delivered
by intramuscular injection of a lentivirus vector pseudotyped
with the vesicular stomatitis virus glycoprotein (VSV-G) not
capable of retrograde transport, or an AAV2 vector capable of
retrograde transport. Both vectors reduced SOD1 protein levels
in skeletal muscle, but the improvement in motor function
was seen solely in the AAV2 treated SOD1 mouse (Miller
et al., 2006). However, partial reduction of mutant SOD1 in
muscle using the Cre-Lox system had no effect on survival
(Miller et al., 2006), and expression of mutant SOD1 in
muscle alone led to motor impairment caused by alterations in
neuromuscular junction (Jaarsma et al., 2008; Wong and Martin,
2010).
Recently, more attention has been given to the potential role of
cortical layer V (upper)motor neuron degeneration in the disease
phenotype. Ozdinler et al. (2011) showed that layer V cortical
motor neurons also undergo degeneration in SOD1G93A mice,
an observation that reproduces the neuropathological findings
in the brain of ALS patients (Saberi et al., 2015). Thomsen et al.
(2014) demonstrated the importance of this neuronal population
in disease progression and as a key therapeutic target: multiple
injections of an AAV-H1-shRNA vector covering the motor
cortex of SOD1 rats led to a 20-day extension in survival with no
evidence of spinal cord transduction. Moreover, this study also
raised questions regarding the hypothesis that ALS is caused by a
“dying back” mechanism—that disease and degeneration starts
in muscle, travels up to the motor neurons of the spinal cord
and eventually to those in the brain. Since suppression of the
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misfolded SOD1 protein inmotor cortex resulted in a therapeutic
benefit, it is possible that disease starts concomitantly at all levels
of the CNS, albeit perhaps with varying kinetics for different
susceptible neuronal populations.
WIDESPREAD DELIVERY THROUGHOUT
THE CNS REMAINS CHALLENGING IN
MOUSE MODELS
AAV9 is highly effective for transduction of spinal cord motor
neurons, in an age dependent manner, but it remains relatively
ineffective for widespread neuronal gene transfer in the brain
by systemic delivery. An alternative approach to achieve broader
neuronal transduction in the CNS is to infuse AAV vectors
into the lateral ventricles of neonatal mice. Stoica et al.,
performed a proof-of-concept experiment using an AAV9 vector
encoding a CBA promoter-driven artificial microRNA specific
to human SOD1, delivered into the brain lateral ventricles
of SOD1G93A mice at post natal day 1 (Stoica et al., 2016).
This type of infusion leads to gene expression in cortical and
spinal cord motor neurons (Broekman et al., 2006; Chakrabarty
et al., 2013; McLean et al., 2014), as well as non-neuronal
cells and peripheral muscle. As a result this study reported
the longest extension in lifespan to date using AAV mediated
RNAi. Interestingly, treated SOD1G93A mice did not die from
the typical onset of paralysis, but instead from rapid body
weight loss accompanied by a progressively hunched kyphotic
posture. A previous study testing the therapeutic efficacy of an
AAV6-amiRNA vector delivered by the same route to neonate
SOD1G93A mice reported development of similar symptoms
unrelated to paralysis (Dirren et al., 2015). The authors of
the AAV9 CBA-amiRNA study postulated the cause of death
to be a previously undetected respiratory phenotype, similar
to the respiratory impairment developed by ALS patients.
Indeed, the reported respiratory phenotype in the ALS mice
was not fully corrected by AAV treatment, making this a
plausible hypothesis to explain the demise of treated mice.
It is important to note that although treated mice survived
longer with no visible motor impairment, there was evidence
of neuronal loss at euthanasia. It is possible that the neurons
involved in respiration—in the medulla, cervical, and thoracic
spinal cord—were lost in these mice, explaining the observed
decrease in respiratory response. Additionally, since this was a
neonatal treatment, the therapeutic artificial microRNA would
have been lost from post-natally dividing cells in the spinal
cord, such as astrocytes. Thus, although this delivery approach
was able to achieve widespread transduction, it is still not an
accurate representation of the transduction achievable in the
clinic as the distribution profile of AAV9 via cerebral spinal fluid
(CSF) infusion routes is considerably more restricted in adult
animals.
The next step for this therapeutic approach is the translation
into adult animals, and larger mammals. The most accessible
way to deliver AAVs into the CSF is through intrathecal (IT)
infusion into the lumbar spinal cord. This injection route leads
to effective transduction of spinal cord motor neurons in adult
non-human primates, but the percentage of transduced neurons
in the brain remains limited. Studies using intrathecal infusions
of AAV vectors in mice reported variable reproducibility, and
limited vector spread to distal spinal cord regions and to the
brain (Snyder et al., 2011). Wang et al. (2014) performed IT
injections of an AAVrh10 vector encoding an artificial miRNA
against SOD1 into the lumbar spinal cord of adult SOD1G93A
mice. This resulted in an 11% average increase in survival
and a direct correlation between survival and the level of
transduction of the spinal cord. Patel et al. performed IT
injections of an AAV1 encoding a single chain antibody against
misfolded SOD1 and reported a 28% increase in survival of
treated SOD1G93A mice. However, survival was highly variable
among treated animals, which directly correlated with antibody
titers in the spinal cord (Patel et al., 2014). This highlights
the still unsolved problem of widespread AAV delivery to
motor neurons in adult mice. Multiple studies have shown
effective transduction of both motor neurons and astrocytes in
non-human primates after CSF infusion (Bevan et al., 2011;
Samaranch et al., 2013; Passini et al., 2014). Presently it is
unclear whether the differences in transduction profiles between
mice and larger species is due to intrinsic differential tropism
across species or technical challenges associated with intrathecal
delivery in mice due to their small size. Nevertheless, Meyer at
al. has recently shown that holding a non-human primate in
the Trendelenburg position following an IT injection enhances
AAV9 spread throughout the spinal cord and into the brain
(Meyer et al., 2015). This type of injection is also feasible in
the clinic, making this delivery technique relevant for clinical
translation.
SUMMARY
Multiple studies have used AAVs to deliver therapeutic RNAi
molecules (Table 1), but none reached the widespread gene
transfer in CNS and periphery thought to be necessary to
achieve transformative outcomes. Intravenous infusion of AAV9
in neonatal mice, such as in transduce peripheral muscle and
mainly motor neurons in the spinal cord, but not in the cortex;
while intravenous infusions in adults transduce mainly glial in
the spinal cord. Lumbar intrathecal AAV injections in adult
mice transduce local motor neurons in the spinal cord, but
few if any in the cortex. Additionally, this type of delivery
method has significant inter-animal variability. Intramuscular
injections using vectors able to undergo retrograde transport
transduce motor neurons, but only those neurons innervating
the injected muscles. Lastly, neonatal intraventricular injections
achieve widespread transduction of cortical and spinal cord
motor neurons, as well as peripheral muscle, but gene expression
is lost from dividing cells, such as astrocytes, which are
known determinants of disease progression. Additionally, SOD1
reduction in upper or lower motor neurons alone is beneficial
but not sufficient to substantially affect the course of disease
progression. The many studies discussed here have clearly
proven the potential of AAV-RNAi gene therapy for treating
SOD1-ALS, and this approach is now also being applied to
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TABLE 1 | Preclinical viral vector mediated RNAi therapeutics for SOD1-ALS.
Animal model Vector Promoter RNAi species
(miR
backbone)
Age at
delivery
Total dose Delivery
method
Survival benefit Study
SOD1G93A
/B6/SJL mouse
VSV-G lentivirus H1 shRNA P40 180 ng of p24
antigen
IT, bilateral None Raoul et al., 2005
SOD1G93A
/B6/SJL mouse
Rabies-G EIAV lentivirus H1 shRNA P7 8.4E7−1.2E8 tu IM, multiple
muscle groups
77% Ralph et al., 2005
SOD1G93A
/B6/SJL mouse
AAV6 H1 shRNA P42 2E11 vg IV none Towne et al., 2008
SOD1G93A
/B6/SJL mouse
AAV6 H1 shRNA P1–P5,
P15
3.7E8 tu IM, multiple
muscle groups
none Towne et al., 2011
SOD1G93A
/B6/SJL mouse
AAV9 H1 shRNA P1 5E11 vg IV 39% Foust et al., 2013
P21 2E12 vg IV 30%
P85 3E12 vg IV 23%
loxSOD1G37R
mouse
P215 3E12 vg IV 22%
SOD1G93A
/FVB/NJ mouse
AAVrh10 CBA amiR (miR30a) 65 2.4e10 vg IT 11% Wang et al., 2014
SOD1G93A
/rat
AAV9 H1 shRNA P70 1.6E11 vg IC (motor cortex) 12% Thomsen et al., 2014
SOD1G93A
/B6 mouse
AAV6 CMV amiR (mir155) P2 1.6E11 vg ICV 26% Dirren et al., 2015
AAV9 GFAP amiR (mir155) P2 6.8E11 vg ICV 14%
AAV6+AAV9 CMV/GFAP amiR (mir155) P2 8E10/3.4E10 vg ICV 10%
AAV9 CMV amiR (mir155) P35 2.4E12 vg IT None
AAV9 GFAP amiR (mir155) P35 2.4E12 vg IT None
SOD1G93A
/B6/SJL mouse
AAVrh10 CB amiR (mir155)
× 2
P56−68 2E11 vg IV 20% Borel et al., 2016
U6 amiR (miR155) P56−68 2E11 vg IV 21%
SOD1G93A
/B6/SJL mouse
AAV9 CBA amiR (mir155)
× 2
P1 1E11 vg ICV 50% Stoica et al., 2016
SOD1, superoxide dismutase 1; AAV, adeno associated viral vectors; VSV, vesicular stomatitis virus; IT, intrathecal; IM, intramuscular; IV, intravenous; IC, intracranial; ICV, intracerebral
ventricular; P, postnatal day; tu, transducting units; vg, vector genomes.
other ALS causative genes (Peters et al., 2015a), but more
potent delivery vehicles are still needed to simultaneously target
all disease-relevant CNS populations in adults. The recent
improvements in injection techniques as well as development of
engineered AAV capsids with vastly improved CNS transduction
efficiency in adult animals are quickly paving the way to
the emergence of potential transformative therapies for ALS
and other neurodegenerative diseases (Choudhury et al., 2016;
Deverman et al., 2016).
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